Newsroom
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Novavax to Participate in Upcoming Investor Conferences
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
Perspectives & Insights
Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.
In the News
See what others are saying about Novavax.
MedCity News
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease
Contagion Live
Novavax COVID-19 Vaccine Linked to Fewer Side Effects in Health Care Workers and First Responders
BiotechTV
After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
Note: This section features articles written by external media outlets and journalists.
About Novavax
We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.
